According to the application of the methylated
transferase G9a / GLP specific inhibitor in preparing the
medicine for treating the fundus
neovascularization diseases, based on an
epigenetics regulation and control mechanism, it is found that the
histone methylated
transferase G9a / GLP specific inhibitor can be used for preparing the
medicine for treating the fundus
neovascularization diseases by inhibiting proliferation, migration and
angiogenesis capacity of
retina microvascular endothelial cells; the composition can effectively block formation and abnormal leakage of fundus
neovascularization in vivo and
in vitro, is good in safety, is applied to treatment of fundus neovascularization diseases for the first time, breaks through action limitation of traditional treatment, and has good application prospects. The technical problems of large administration trauma,
poor compliance, single action mechanism, high
drug resistance risk, incapability of
radical treatment, heavy economic burden and the like in the existing fundus neovascularization treatment technology are solved, and a novel treatment scheme which is wide in action target spot, good in safety, convenient in administration, controllable in cost and capable of regulating and controlling the
pathological process from the upstream is provided. The application blank of the epigenetic inhibitor in the field of
ophthalmology neovascularization treatment is filled.